<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16657">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939509</url>
  </required_header>
  <id_info>
    <org_study_id>1445</org_study_id>
    <nct_id>NCT01939509</nct_id>
  </id_info>
  <brief_title>Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol</brief_title>
  <acronym>CHAB</acronym>
  <official_title>Comparison of the Hemodynamic Changes in Patients Under Treatment With Bisoprolol Versus Atenolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At hemodynamic level, the greater affinity of bisoprolol by the beta 1 receptor in theory
      could improve the peripheral arterial perfusion and could have a greater antihypertensive
      effect. At the same time, this could carry objectifiable improvements in the vascular tree,
      such as the level of arterial stiffness.

      This study attempts to mark the hemodynamic differences in the same individual with
      hypertension and metabolic syndrome who will be exposed to both drugs at different moments.
      Parameters will be objectified with impedance cardiography, pulse wave velocity and central
      blood pressure assessment before and after taking each one of the drugs. The results will be
      compared to the baseline data and between themselves.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>central blood pressure</measure>
    <time_frame>two months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>peripheral resistance</measure>
    <time_frame>two months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac index</measure>
    <time_frame>two months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse wave velocity</measure>
    <time_frame>two months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertension</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Atenolol-Bisoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)</description>
    <arm_group_label>Atenolol-Bisoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol</intervention_name>
    <arm_group_label>Atenolol-Bisoprolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension

          -  Metabolic syndrome

        Exclusion Criteria:

          -  Severe hypertension &gt;180/110

          -  Secondary hypertension

          -  Contraindication for betablockers

          -  Prior treatment with betablockers (up to one month before inclusion)

          -  History of neoplastic disease

          -  Patients that do not sign informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel D Waisman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucas S Aparicio, MD</last_name>
      <phone>(005411)49590200</phone>
      <phone_ext>8567</phone_ext>
      <email>lucas.aparicio@hospitalitaliano.org.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas S Aparicio, MD</last_name>
      <phone>49590200</phone>
      <email>lucas.aparicio@hospitalitaliano.org.ar</email>
    </contact>
    <contact_backup>
      <last_name>Diego Giunta, MD</last_name>
      <phone>49590200</phone>
      <phone_ext>4419</phone_ext>
      <email>diego.giunta@hospitalitaliano.org.ar</email>
    </contact_backup>
    <investigator>
      <last_name>Lucas Aparicio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>c118ach</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas aparicio, MD</last_name>
      <phone>49590200</phone>
    </contact>
    <investigator>
      <last_name>Lucas S Aparicio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>February 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Lucas Aparicio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
